R-Ras coordinates reciprocal activation of ERK5 and ERK1/2 under single pathway inhibition in melanoma

Malignant melanoma is frequently driven by constitutive activation of the RAS-RAF-MEK1/2-ERK1/2 pathway, yet adaptive signaling limits the long-term efficacy of MAPK-targeted therapies.

Malignant melanoma is frequently driven by constitutive activation of the RAS-RAF-MEK1/2-ERK1/2 pathway, yet adaptive signaling limits the long-term efficacy of MAPK-targeted therapies. Although activation of the MEK5-ERK5 pathway has emerged as a mechanism of resistance to…